Preparation of Hyaluronic acid-based Nanopolymersomes for Breast Cancer Treatment: In vivo analysis
Paper ID : 1163-ICNS
Mahsa Shahriari *1, Mona Alibolandi2, Mohammad Ramezani1
1Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences
2Department of Pharmaceutical Biotechnology, Mashhad University od Medical Sciences
In the current research, the synthesis of polysaccharide-based polymersomes for targeted delivery of doxorubicin is reported. To this aim, doxorubicin was encapsulated in aqueous compartment of hyaluronan-polycaprolactone polymersomes via nanoprecipitation method. In the previous study of this group, the therapeutic index of the prepared formulation was studied in metastatic breast cancer model in vitro. In this study, we reported in vivo analysis of hyaluronic acid-based polymersomes in breast cancer treatment. The size of obtained polymersomes was 146.2 ± 9.6 nm and offered the efficiency of encapsulation and the content of loading %54.9 ±4.0 and %3.6 ±0.4, respectively. The obtained results exhibited that the HA-PCL polymersomes controlled the release of DOX in a sustained manner. Much better in vivo antitumor efficacy and wider tumour tissue necrosis and better bio-distribution features of this formulation in comparison with PEG-PCL-DOX nanoparticles suggested that HA-PCL-DOX can potentially reduce off-target effects due to its targeting capability.
“Nanopolymersome”, “Doxorubicin”, “Hyaluronic acid”, “Breast cancer”, “Polycaprolactone”.
Status : Abstract Accepted (Poster Presentation)